Skip to main content
Events
GroupKALSHI

What will the average number of measles cases be during Trump's term?

What will the average number of measles cases be during Trump's term?
Vol

$0.00

|
Events

1

|
Markets

7

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

87%
Top Probability
$0.00
Volume
7
Markets
1
Platforms

About This Event

From 2025 to 2028 If the average number of measles cases annually from 2025 to 2028 is at least X then the market resolves to Yes.

Current Market Outlook

Kalshi traders are pricing an 87% probability that the average annual number of measles cases during Trump's second term (2025–2028) will hit at least 2,000. That is high confidence. For context, the U.S. averaged roughly 120–375 cases per year between 2010 and 2019, then saw a spike to 1,282 in 2019 before the pandemic drove cases to near zero. The market is betting that the post-COVID return to pre-2019 trends will overshoot significantly.

Key Factors Driving the Odds

Two big forces are pushing this number up. First, the 2019 outbreak showed how quickly measles can resurge when vaccination rates slip. The CDC reported that 2019 had the highest case count since 1992, driven by pockets of unvaccinated children in communities with low MMR uptake. Second, the post-2020 rebound is already visible: 2024 saw 285 cases by October, a pace that would exceed the 2015–2018 average. With Trump's administration historically skeptical of federal vaccine mandates and public health messaging, the market expects those trends to accelerate.

The Trump team's 2024 campaign platform included reducing CDC authority and rolling back school vaccine requirements. States like Florida and Texas, which already have lower MMR coverage rates, could see outbreaks compound. The 2,000 threshold is roughly 5–6x the pre-2019 baseline, which is plausible if one or two large outbreaks occur in undervaccinated metro areas.

What Could Change These Odds

A drop below 87% would require a sharp reversal in vaccination rates or a major public health push that the market does not currently expect. If the Trump administration surprises by maintaining CDC funding for vaccine outreach, or if Congress funds a national catch-up campaign, cases could stay below 2,000. The 2028 end date also matters: a severe outbreak in 2025 could pull the average up, but if the first two years are quiet, the odds could fall. The only scheduled catalyst is the 2025 federal budget cycle, where vaccine program funding will be debated. If cuts are deeper than expected, the probability could climb toward 95%.

Cross-Platform Analysis

No other prediction markets are trading this contract. Kalshi is the sole platform. The 87% price implies a 13% chance that cases stay below 2,000. That is a narrow margin for a counter-trend bet, but not unreasonable given the unpredictable nature of disease transmission and policy shifts.

AI-generated analysis based on market data. Not financial advice.

Overview

Measles is a highly contagious viral disease that can cause severe complications, including pneumonia and encephalitis. The United States declared measles eliminated in 2000, meaning no continuous transmission for over 12 months. However, outbreaks have re-emerged in recent years, driven largely by declining vaccination rates. The prediction market asks: what will the average number of measles cases be annually from 2025 to 2028, during President-elect Donald Trump's second term? This period covers January 2025 to December 2028. The market resolves to Yes if the annual average meets or exceeds a threshold set by the market creator. The question reflects growing concern about public health infrastructure, vaccine hesitancy, and the potential impact of federal policies under a new administration. Trump has previously expressed skepticism about vaccines, and his administration's first term saw the elimination of the National Security Council's global health security unit. The COVID-19 pandemic further eroded routine vaccination coverage, with CDC data showing kindergarten vaccination rates for MMR fell from 95.2% in the 2019-2020 school year to 93.1% in 2022-2023. This drop, while small in percentage, can significantly increase outbreak risk. Measles cases in the U.S. have fluctuated: 1,282 cases were reported in 2019, the highest since 1992, before falling to 13 in 2020 due to pandemic restrictions. Since then, cases have risen again, with 121 cases in 2022 and 59 in 2023. As of late 2024, the CDC reported over 280 cases for the year, suggesting an upward trend. The outcome of this market will depend on vaccination coverage, state-level exemption policies, and federal public health priorities under the new administration.

Historical Context

Measles was a common childhood illness before the vaccine was introduced in 1963. In the pre-vaccine era, the U.S. saw 3 to 4 million cases annually, with 48,000 hospitalizations and 400 to 500 deaths each year. The measles, mumps, and rubella (MMR) vaccine, licensed in 1971, drove cases down dramatically. By 2000, the CDC declared measles eliminated from the U.S. Elimination does not mean zero cases; it means no continuous transmission for more than 12 months. Imported cases from travelers continue to occur. The first major post-elimination outbreak was in 2014-2015, linked to Disneyland in California, resulting in 147 cases across seven states and Mexico. That outbreak was traced to an unvaccinated traveler and exposed gaps in herd immunity. In response, California passed SB 277 in 2015, eliminating personal belief exemptions for school vaccinations. Other states like New York and Washington later tightened exemption policies. The 2019 outbreak was the largest since elimination, with 1,282 cases concentrated in Orthodox Jewish communities in New York and Washington. The outbreak was linked to travelers from Israel and Ukraine, where vaccination rates were low. New York City declared a public health emergency and mandated vaccinations in affected neighborhoods. The COVID-19 pandemic disrupted routine healthcare globally. The CDC reported that kindergarten MMR vaccination coverage fell from 95.2% in 2019-2020 to 93.1% in 2022-2023, meaning about 250,000 kindergartners were not vaccinated against measles. The World Health Organization reported a global measles resurgence in 2023-2024, with a 79% increase in cases in 2023 compared to 2022. The U.S. has already seen outbreaks in 2024 linked to migrant shelters and unvaccinated communities.

Why It Matters

Measles is one of the most contagious diseases known. One infected person can spread it to 12 to 18 others in a susceptible population. The virus can linger in the air for up to two hours after an infected person leaves a room. Even a small decline in vaccination coverage can trigger outbreaks. Each measles case carries a risk of hospitalization (about 20% of cases), pneumonia (1 in 20 children), encephalitis (1 in 1,000), and death (1 to 3 per 1,000). The economic cost of an outbreak is substantial. The 2019 outbreak in New York cost the city and state an estimated $8.4 million in public health response, including contact tracing, quarantine, and vaccination campaigns. Nationally, the CDC spent $3.7 million on the outbreak. Beyond immediate health costs, outbreaks erode public trust in health systems and can lead to school closures and missed work. The political stakes are high. The Trump administration's stance on vaccines will be closely watched. If the administration appoints vaccine skeptics to key health positions, it could signal a shift away from evidence-based policy. This could accelerate the decline in vaccination rates, leading to more outbreaks. Conversely, a strong federal response could reinforce the importance of vaccination. The outcome of this market will reflect the effectiveness of U.S. public health infrastructure in the face of political headwinds.

Was this helpful?
Updated Jul 28, 2026

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

Market Insights

Average Yes Price
54¢
Kalshi
Arbitrage Opps
0
Cross-Platform
0

Trade This Market